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EGF-receptorE5 oncoprotein activity from high risk human papillomaviruses (HPVs) is associated with growth factor
receptor signaling, but the function of this protein is not well understood. In this study, we investigated the
role of HPV-16 E5 on the cell cycle progression during EGF-stimulation. Wild-type and NIH 3T3 cells over-
expressing human EGF-receptor were transfected with HPV-16 E5 gene and the cell cycle progression was
characterized. This analysis showed that the E5-expressing cells increased DNA synthesis (S-phase) by
around 40%. Cell cycle protein analysis of E5-expressing cells showed a reduction in the half-life of p27Kip1
protein as compared to control cells (18.4 vs. 12.7 h), an effect that was enhanced in EGF-stimulated cells
(12.8 vs. 3.6 h). Blockage of EGF-receptor activity abrogated E5 signals as well as p27Kip1 down-regulation.
These results suggest that E5 and the EGF-receptor cooperate to enhance cell cycle entry and progression
through regulating p27Kip1 expression at protein level.ancer Center for Research on
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Mammalian cell proliferation is controlled by extra-cellular
growth factors that initiate a cascade of events, ultimately leading
to cell growth, division and proliferation. Progression through the cell
cycle is regulated by a series of cyclin-dependent protein kinases
(CDKs) and the association of CDKs with cyclins is required for their
activation. In addition to positive regulation by cyclins, CDK activity is
also negatively controlled through association with CDK inhibitors
(CKIs) to block the cell cycle progression (Besson et al., 2008; Morgan,
1995; Sherr and Roberts, 1995; Sherr and Roberts, 1999). The
mammalian CKIs fall into two families. The ﬁrst family, denominated
Ink4 (Cánepa et al., 2007), includes p16Ink4A (Serrano et al., 1993),
p15Ink4B (Hannon and Beach, 1994), p18Ink4C (Guan et al., 1994; Hirai
et al., 1995), and p19Ink4D (Chan et al., 1995; Hirai et al., 1995), that
speciﬁcally inhibit CDK4 and CDK6. The second family includes
p21Cip1 (Abbas and Dutta, 2009; El-Deiry et al., 1993; Gu et al., 1993;
Harper et al., 1993), p27Kip1 (Borriello et al., 2007; Hengst and Reed,
1996; Polyak et al., 1994b; Vervoorts and Lüscher, 2008) and p57Kip2
(Lee et al., 1995; Matsuoka et al., 1995), that interact and inhibit a
broad range of CDKs. One of the most abundant CKIs is p27Kip1 whichis expressed at high levels in quiescent cells (Hengst and Reed, 1996;
Hitomi et al., 2006), in cells arrested in G1 by cell–cell contact
inhibition (Kato et al., 1997; Yanagisawa et al., 1999), in the presence
of transforming growth factor beta (TGF-β) (Polyak et al., 1994a;
Reynisdottir et al., 1995), or cyclic AMP (Kato et al., 1994). Conversely,
some growth factor signals such as IL-2 and epidermal growth factor
(EGF) appear to stimulate cell proliferation in part through degrada-
tion of p27Kip1 (Nourse et al., 1994; Takuwa and Takuwa, 1997).
Recently, it has been proposed that p27Kip1 protein works in a
negative feedback loop regulating Grb2 in response to mitogen
stimulation, inhibiting the Ras signal transduction pathway (Moeller
et al., 2003). Other reports have shown that low levels of p27Kip1
protein correlate with tumor progression and poor patient survival in
many human cancers (Abukhdeir and Park 2008; Bahnassy et al.,
2007; Catzavelos et al., 1997; Mori et al., 1997).
On the other hand, during cancer development, it has been
observed that viral oncoproteins from papillomavirus, adenovirus or
SV40, target cell cycle proteins and manipulate the cell towards the
transformed phenotype. In the case of HPV, the main etiological agent
for cervical cancer, the E6 and E7 are the main viral oncoproteins
(Muñoz et al., 1994;Wise-Draper andWells, 2008; zur Hausen, 1996).
The E7 oncoprotein binds to and inactivates the cellular tumor
suppressor retinoblastoma protein pRb and related proteins (Bere-
zutskaya et al., 1997; Dyson et al., 1992). Meanwhile, E6 promotes the
degradation of the cellular tumor suppressor p53 through the
association of E6-AP by the ubiquitin proteolytic pathway (Hubbert
Fig. 1. Expression of HPV-16 E5 transcripts in transfected cells. RT-PCR reactions were
carried out to amplify the E5 speciﬁc fragment of 275 bp as described in Materials and
methods. The pcDNAE5 plasmid was used as positive control. DNA molecular weight
markers are in base pairs (bp). The characteristics of the different transfected cell lines
are shown in the table.
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Tungteakkhun and Duerksen-Hughes, 2008; Werness et al., 1990).
Recently, the E5 gene from HPV-16 was identiﬁed as another
potential oncogene (Bouvard et al., 1994; Genther Williams et al.,
2005; Leptak et al., 1991; Maufort et al., 2007; Pim et al., 1992). The E5
protein is highly hydrophobic and it is associated with cell
membranes (Conrad et al., 1993; Lewis et al., 2008; Oetke et al.,
2000; Suprynowicz et al., 2008). A number of reports have
demonstrated that E5 increases the half-life of EGF-receptor (Genther
Williams et al., 2005; Martin et al., 1989; Rodriguez et al., 2000;
Straight et al., 1993, 1995; Tomakidi et al., 2000), possibly by
interacting with the 16 kDa subunit of the H+-ATPase and then
inhibiting the acidiﬁcation of endosomes (Briggs et al., 2001; Conrad
et al., 1993; Di Domenico et al., 2009; Straight et al., 1995). In contrast,
results from other studies indicate that HPV-16 E5 protein binds to,
but does not disturb the activity of the vacuolar H+-ATPase (Adam et
al., 2000; Ashby et al., 2001; Rodriguez et al., 2000), suggesting that E5
exerts its function through another mechanism (Kivi et al., 2008).
Moreover, E5 also affects the activity of other members of the EGF-
receptor family like ErbB2 (Crusius et al., 1998) or ErbB4 (isoform JM-
b/cyt-1) (Chen et al., 2007) and components of the EGF signaling
pathway, like MAPKs (ERK1 and ERK2) (Crusius et al., 1997; Gu and
Matlashewski, 1995; Kim et al., 2006; Zhang et al., 2002). It was also
reported that E5 favors the over-expression of transcriptional factorsTable 1





Doubling time (h)a Satur
−EGF +EGF −EGF
3T3neo pcDNA3 17.2 17.3 1.71±
3T3E5 pcDNAE5 17.1 17.3 2.03±
EGFRneo pcDNA3 19.0 19.6 0.98±
EGNE5 pcDNAE5 21.3 18.5e 1.28±
a Numbers given are average of triplicate determinations.
b Number of cells are given by 1×106. Average of duplicate experiments and their interv
c Cells were seeded at 1×104 and grown in soft agar for 15 days in the absence or presen
Numbers given are average of duplicate determinations.
d Ratio, number of colonies in agar relative to control 3T3neo cells.
e p value b0.05 when comparing EGFRneo vs. EGNE5 cells calculated by Mann–Whitneyinvolved in cell growth such as c-Fos and c-Jun that form the AP-1
complex (Chen et al., 1995, 1996a, 1996b). However, c-jun antisense
DNA treatment can only partially suppress the transforming function
of HPV-11 E5, suggesting the existence of other mechanisms for E5-
mediated cell transformation (Chen et al., 1994; Kivi et al., 2008). In
this sense, it has been demonstrated that E5 proteins from HPV-11
and -16 repress p21WafI gene expression in ﬁbroblasts and keratino-
cytes promoting cell proliferation (Nath et al., 2006; Tsao et al., 1996).
Another CKI modiﬁed by the oncogenic E5 protein, but from bovine
papillomavirus type 4, is p27Kip1. It has been shown that E5/E8
protein promotes the elevation of p27Kip1 protein levels and prevents
the correct function of this protein, allowing cell proliferation in the
absence of mitogens (O'Brien et al., 2001). A similar role of HPV-16 E5
protein has not been described up to date. Because of this, we set out
to elucidate the molecular pathway by which E5 regulates cell cycle
progression and allows the initiation of the transformation process.
We found that HPV-16 E5 is able to enhance the down-regulation of
p27Kip1 protein in an EGF-receptor dependent pathway, as the
downstream target Grb2 protein is maintained active for a longer
period of time than the controls after the receptor stimulation. These
events, generated by the presence of HPV-16 E5 oncoprotein, allow
cells to enter to and prolong the S-phase of the cell cycle, which may
be important for the transformation process.
Results
Characterization of cells expressing the HPV-16 E5 oncogene
To characterize for the expression of HPV-16 E5 transcripts in the
transfected NIH3T3 cells (as no antibodies are available for E5
protein); total RNA was extracted from all transfected cell lines and
RT-PCR assays were performed. The results revealed that only the
3T3E5 and the EGNE5 cells showed a band of approximately 275 bp
that corresponds to the ORF of E5 cloned into the pcDNA3 plasmid. At
the same time, RT-PCR of parental cells (3T3neo and EGFRneo) was
carried out as negative control of the system (Fig. 1).
After examination of E5 expression in the transfected cell lines, we
next studied the transforming/oncogenic activity of this protein
(Table 1). Growth kinetics analysis revealed that there were no
differences on the doubling time in the EGFRneo cells in the absence
or presence of EGF (19 vs. 19.6 h, respectively). However, the EGNE5
cells (expressing E5 and EGF-receptor) showed the slower doubling
time (21.3 h in−EGF) than the rest of the cell lines. Interestingly, the
doubling time decreased to 18.5 h when EGFwas added to the system,
difference that was statistically signiﬁcant when compared to the
parental EGFRneo cells (pb0.05). This result suggests that E5
expression in the EGNE5 cells could be modifying the length of the
cell cycle. Under the same conditions, the saturation density was 40%
higher in the EGNE5 cells than in the parental EGFRneo cells, in the
presence of EGF (2.96×106 vs. 2.11×106, respectively) difference that
was statistically signiﬁcant (pb0.05), even though the cell densitiesation density (106)b No. of colonies in soft agarc
+EGF −EGF (ratio)d +EGF (ratio)d
0.04 2.43±0.35 1.5 (1) 5.5 (1)
0.04 2.56±0.10 0.0 (0) 1.0 (0.2)
0.03 2.11±0.12 132 (88) 296 (54)
0.04 2.96±0.11e 16 (11) 702 (128)
als are presented.
ce of 25 ng/ml EGF. Similar results were obtained in another independent experiment.
test.
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respectively). In the case of 3T3E5 cells, the doubling time and the
saturation density were similar to the parental 3T3neo cells.
We then sought to determine the transforming capacity of E5
associated to EGF-receptor activity as it has been reported (Genther
Williams et al., 2005; Pim et al., 1992), by measuring anchorage-
independent growth in soft agar (Table 1). It was observed that
EGNE5 cells expressing E5 and over-expressing the EGF-receptor had
reduced transformation capacity in the absence of EGF, as a lower
number of colonies were detected (ratio 11 vs. 88 from EGFRneo
cells), an effect that was consistently observed in three independent
experiments (data not shown). However, the transforming capacity of
E5 in EGNE5 cells was totally restored and sometimes, even higher
than the parental EGFRneo cells, when EGF was added to the system
(ratio 128 vs. 54, respectively). On the other hand, the 3T3E5 cells
were unable to form colonies in agar, either in the absence or presence
of EGF as previously reported (Pim et al., 1992). The 3T3neo cells were
used as negative control for transformation (−/+EGF conditions; 1.5
and 5.5 colonies, respectively). Meanwhile, the positive control
EGFRneo cells over-expressing the EGF receptor proto-oncogene
had increased levels of colony formation in agar in conditions with or
without EGF (ratio 88 and 54, respectively). The different behaviors
observed between the E5-expressing cells (3T3E5 and EGNE5) could
be due to the fact that over-expression of the EGF-receptor in the
EGNE5 cells ampliﬁes the activity of the E5 protein.
Cell cycle distribution is altered by the presence of E5 from HPV-16
After demonstrating that E5-expressing cells have modiﬁed
proliferation rate and increased transforming activity, we looked for
alterations in cell cycle phases through FACS analysis (Fig. 2). CellsFig. 2. Cell cycle analysis of E5-expressing cells. Cells were grown in the presence of 50 ng/
distribution of the population was determined by FACS analysis. Cell cycle histograms are sh
table shows the distribution of cells in the different cell cycle phases, as determined by thewere grown in the presence or absence of EGF for 16 h prior to FACS
analysis. Cells expressing E5 (3T3E5 and EGNE5) and stimulated with
EGF showed an important increase in S-phase cells of 37% (from 15.5%
to 21.2%) and of 44% (from 17.7% to 25.5%) respectively, when
compared with non-stimulated cells. It is notable that in parental cells
(3T3neo and EGFRneo), the increase in S-phase in the presence of EGF
was only around 17%, as compared with non-stimulated cells. These
results suggest that E5 expression increases the S-phase cell
population, independent of the number of EGF-receptors, as the
EGFRneo cell line that over-expresses the receptor was unable to
increase the S-phase to the same extent as the E5-expressing cell
lines.
E5 from HPV-16 alters p27Kip1 protein levels in EGF stimulated cells
As expected, our results conﬁrmed that E5 possesses transforming
activity. However, it was also important to show that HPV-16 E5 is
able to alter the S-phase of the cell cycle. A possible explanation is
that E5 protein might regulate the levels of one or several cell cycle
regulators. To test this hypothesis, we analyzed the cell cycle protein
expression pattern by Western blot in the presence of EGF at
different times in parental and E5-expressing cells (Fig. 3). The
results showed that 3T3E5 and EGNE5 cells, but not the parental cells
(3T3neo and EGFRneo) showed a remarkable decrease in the p27Kip1
protein levels after 16 h of EGF-stimulation (b35% left in E5-
expressing cells as compared to parental cells) and stayed low even
after 24 h post-stimulation (b27% left in E5-expressing cells vs. 67%
in EGFRneo cells and 105% in 3T3neo cells) (Fig. 3, 3T3E5 and
EGNE5). These results showed that p27Kip1 protein levels decreased
in E5-expressing cells and remained low for longer time when the
EGF-receptor was activated.ml EGF for 16 h, harvested, ﬁxed with ethanol and stained with 10 μg/ml PI. Cell cycle
own from the different cell lines stimulated with EGF at 0 (−) and 16 h (+) times. The
WinMDI 2.8 software.
Fig. 3. Effect of HPV-16 E5 protein on cell cycle proteins. Transfected cells were stimulated with 50 ng/ml EGF at different times. Forty micrograms of total protein from each cell line
was separated by SDS-PAGE, followed by immunoblot analysis with antibodies against different cell cycle proteins, and developed by chemiluminescence. Immunoblots from 3T3neo
and EGFRneo (control cells), and 3T3-E5 and EGNE5 (E5-expressing cells) were tested with different cell cycle protein antibodies. Actin blots were used as loading controls of the
system.
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the E5 signal and clear differences between the parental EGFRneo and
the EGNE5 cell lines were observed, subsequent experiments were
carried out only with these two cell lines.
HPV-16 E5 oncoprotein down-regulates p27Kip1 through reduction of
protein half-life
To further characterize the mechanism for p27Kip1 down-regula-
tion, we treated cells with cycloheximide to stop protein synthesis
and then stimulated the cells with EGF at different times (described in
Materials and methods), to examine p27Kip1 protein degradation and
calculate its half-life.Western blot analysis showed that right from the
start p27Kip1 protein levels were lower in the E5-expressing cells than
in parental EGFRneo cells. However, the down-regulation of p27Kip1
was enhanced in the E5-expressing cells following EGF-stimulation.
This effect became evident at 6 h and the protein levels were almost
depleted by 8 h (Fig. 4A, EGNE5). Through densitometric analysis, we
calculated the total pixels contained in each p27Kip1 band using the
ImageJ program (version 1.33u, NIH-USA). The data was plotted in a
graph (Fig. 4B) and used to calculate the half-life of p27Kip1 protein
according to Belle et al. (2006). Throughout these data, it was clear
that the half-life of p27Kip1 protein in E5-expressing cells was slightly
reduced in the absence of EGF when compared with parental EGFR
cells (from 18.4 to 12.7 h). At the same time, in the presence of EGF,
p27Kip1 half-life was reduced four-fold when compared with control
cells (from 12.8 to 3.6 h) (Fig. 4C). Together, these results suggest that
E5 cooperates with the EGF-receptor to promote cell proliferation by
maintaining low levels of p27Kip1 protein through reducing the
protein stability of p27Kip1.
Consistent with our results, it has been reported that p27Kip1
expression is mainly regulated at post-translational level by ubiqui-
tination mediated proteolysis (Swanson et al., 2000; Ungermannova
et al., 2005). Despite this, we also investigated the regulation of
p27Kip1 by E5 and EGF-signaling. Northern blot analysis for p27Kip1
showed similar p27Kip1 mRNA levels in parental and E5-expressing
cells when stimulated with EGF (data not shown). Based on theseresults, we propose that E5 has little or no effect on p27Kip1 regulation
at the transcriptional level, but functions predominantly at post-
translational level.
EGF-receptor protein levels are down-regulated in E5-expressing cells,
but receptor activity is maintained for a longer period of time
Many studies have reported that E5-expressing cells have a
prolonged EGF-receptor activity as a result of receptor recycling
(Martin et al., 1989; Rodriguez et al., 2000; Straight et al., 1993,
1995). Therefore, we investigated the levels and activity of the EGF-
receptor through Western blotting and correlated the tyrosine
phosphorylation with p27Kip1 down-regulation in response to E5
oncoprotein signaling. The results showed that EGF-receptor activity
(observed by receptor tyrosine phosphorylation) was similar in the
E5-expressing cells an in EGFRneo cells at time 0, but receptor
activity was kept high for a longer period of time (up to 24 h) in
EGNE5 cells than the parental EGFRneo cells (Fig. 5A, EGF-r-Tyr-P).
However, lower EGF-receptor protein levels were detected in EGNE5
cells than in parental EGFRneo cells by 24 h post receptor-
stimulation (Fig. 5A, EGF-r). At the same time, EGF-receptor activity
correlated with the down-regulation of p27Kip1 protein levels in E5-
expressing cells (Fig. 5A, p27Kip1). Comparative analysis of the EGF-
receptor tyrosine phosphorylated bands showed that the basal
activity of the EGF-receptor was similar in both cell lines, however
after 16 h post EGF-stimulation the receptor activity was 3.5 fold
higher in the E5-expressing cells than in the parental EGFRneo and
remained high (3 fold) in EGNE5 cells even after 24 h post EGF-
stimulation (Fig. 5B). We also found that EGF-receptor transcripts
were not modiﬁed by EGF stimulation, since the Northern blot of
the different cell lines showed similar levels of receptor mRNA (data
not shown), which suggests that E5 was modulating the EGF-
receptor at the post-translational level. Taken together, these results
indicate that E5-expressing cells maintained a higher activity of
the receptor (tyrosine phosphorylation), than parental EGFRneo
cells, although parental cells showed twice as much receptor protein
(Fig. 5A).
Fig. 4. E5 from HPV-16 alters p27Kip1 half-life. Parental EGFRneo and EGNE5 cells were
pre-treated with 5 μg/ml CHX for 30 min and later stimulated with 25 ng/ml EGF at
different times. Immunoblot analysis was performed with 40 μg of total protein and
developed with monoclonal anti-p27Kip1 antibody by chemiluminescence. (A) Blots
from the different cell lines showing the p27Kip1 protein after different times of EGF
stimulation. (B) Bands from panel (A) were scanned and relative amounts of p27Kip1
protein were plotted in a graph versus time of EGF stimulation. (C) p27Kip1 protein half-
life was calculated from data taken from (B) according to Belle et al. (2006).
Fig. 5. Protein and phosphorylation levels of EGF-receptor in E5-expressing cells. (A)
Cells were stimulated with EGF for 16 h, lysed, separated on 15% SDS-PAGE and tested
by immunoblot with anti-EGF-receptor and anti-phosphotyrosine (PY99) antibodies.
Blots were developed by chemiluminescence. Actin was used as loading control of the
system. (B) EGF-receptor protein and phosphorylated bands from the immunoblots
were scanned and the relative intensity of bands calculated with the ImageJ program
(version 1.33u, NIH-USA). A receptor stimulation index was calculated by dividing
intensity of phosphorylated bands vs. intensity of EGF-receptor total protein. A graph of
receptor stimulation index was plotted versus time of EGF stimulation.
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To verify that the effect of E5 on p27Kip1 down-regulation depends
on EGF-receptor activity, we used tyrphostin-AG1478, a speciﬁc
inhibitor of the receptor kinase activity to block EGF-receptor
signaling (Zhu et al., 2001). PDGF-receptor tyrosine phosphorylation
was used as a negative control for the system. Cells were grown and
stimulated with EGF as described in Materials and methods. Western
blot analysis showed that EGF-receptor was activated after 30 min
post EGF-stimulation in the presence or absence of E5 protein (Fig. 6;
lanes 2 and 14). However, in E5-expressing cells there was an
increased activity of the EGF-receptor in every measurement (Fig. 6;
EGNE5, upper panel). Addition of tyrphostin-AG1478 to the cells prior
to EGF-stimulation demonstrated inhibition of EGF-receptor activity
as revealed by the absence of tyrosine phosphorylation (Fig. 6; lanes 3
and 15, upper panels). By 16 h post-EGF stimulation, higher levels of
phosphorylated EGF-receptor and lower levels of p27Kip1 protein
were observed in EGNE5 cells compared with EGFRneo cells (Fig. 6;
lanes 8 and 20, upper and p27Kip1 panels). In the presence of
tyrphostin-AG1478, p27Kip1 down-regulation was blocked as a
consequence of speciﬁc EGF-receptor activity inhibition (Fig. 6;
lanes 10 and 22, upper and p27Kip1 panels). On the other hand,
p27Kip1 protein levels were not affected by the inhibitor in the PDGF
system at any time (Fig. 6; p27Kip1 panel, lanes 12 and 24). To identify
if the signal transduction system of the EGF-receptor was completelyblocked by tyrphostin-AG1478, we studied the phosphorylation of the
downstream EGF-receptor target Grb2 protein (Li et al., 2001). The
results for the parental EGFRneo cells showed a normal pattern of
Grb2 protein phosphorylation in the presence of EGF at short time
points, although this activity was reduced to 13% after 16 h post-
stimulation (Fig. 6; lanes 2 vs. 8, respectively). However, for E5-
expressing cells 28% of Grb2 protein remained phosphorylated by 16 h
post-stimulation, suggesting the presence of a positive stimulation of
the EGF-receptor signal-transduction system (Fig. 6; lanes 14 vs. 20).
These results showed that E5 requires an active EGF-receptor
(receptor phosphorylation) and an active receptor pathway (Grb2-
phosphorylation) to enhance the down-regulation of p27Kip1 protein
levels. However, at this point we still do not know which pathway
from the EGF-receptor is involved in the down-regulation of p27
associated to E5 activity, as more experiments need to be done to
dissect this part.
Discussion
In this paper, we report that HPV-16 E5 protein is involved in the
down-regulation of p27Kip1 levels, a CDK inhibitor important for G1
cell cycle arrest. This novel property of HPV-16 E5 protein requires an
active EGF-receptor as well as an active receptor signal cascade (Grb2-
phosphorylation), a ﬁnding that has also been demonstrated for other
signals associated with this oncoprotein (Crusius et al., 1997, 1998;
Leechanachai et al., 1992; Pim et al., 1992; Straight et al., 1993).
Recently, the HPV-16 E5 gene is regarded as a potent oncogene,
because of its ability to promote persistent growth of spontaneous
tumors in E5 transgenic mice in the absence of E6/E7 oncogenes.
Moreover, the cooperation between E5 and EGF-receptor was also
supported in those experiments (Genther Williams et al., 2005).
When we studied transformation activity in E5-expressing cells,
we observed that E5 requires the activation of the EGF-receptor to
Fig. 6. HPV-16 E5 down-regulation of p27Kip1 protein levels is dependent of EGF-receptor activity. EGFRneo and EGNE5 cells were treated with 1 μM tyrphostin-AG1478 for 1 h prior
to EGF (50 ng/ml) or PDGF (25 ng/ml) stimulation. Cells were lysed in RIPA buffer supplemented with 10 mM sodium orthovanadate and 0.5 mM DTT. Forty micrograms of total
protein was separated on 12.5% SDS-PAGE, followed by immunoblot analysis with anti-phosphotyrosine (PY99), anti-p27Kip1, anti-Grb2 or anti-actin antibodies as control. Proteins
were visualized by chemiluminescence.
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expressing cells (EGNE5) induced the highest saturation density and
colony formation in soft agar (characteristics associated with a
transformed phenotype), only in the presence of EGF as previously
reported (Leechanachai et al., 1992; Martin et al., 1989; Pim et al.,
1992; Straight et al., 1993). Over-expression of the EGF-receptor
confers transforming capacity in the cells, as shown by the high
number of colonies in EGFRneo cells. However, it was striking that
colony formation was reduced in E5-expressing cells in the absence of
EGF, but enhanced 128 fold over the control (3T3neo) cells in the
presence of EGF. At this moment, it is not clear how E5 could abrogate
the transformation process, but it was apparent that activation of the
EGF-receptor is required for the E5 signaling pathway to function and
induce transformation. One possibility is that, in the absence of ligand,
E5 decreases spontaneous dimerization and signaling of EGF-receptor,
allowing the modulation of the transformation process or could lead
the cells to another cellular process like senescence or differentiation.
Our results are in agreement with the recent report of Genther
Williams et al. (2005), who demonstrated in transgenic mice that E5
was able to direct cells to differentiation and not only to transforma-
tion, however, it was not clear if these events depend on EGF-receptor
activation.
Our results also showed that E5, in cooperation with EGF-receptor
signaling, promoted cellular proliferation; this was demonstrated by
an increase in the S-phase cell population in EGNE5 cells (Fig. 2).
These results are consistent with another report that showed that
HPV-31 E5 protein supports cell cycle progression in epithelial
differentiating cells (Fehrmann et al., 2003), although these research-
ers postulate that EGF-receptor is not involved in the process. This
result, disagrees with our ﬁndings, might be due to the presence of E6
and E7 in the same cellular system. It is possible that E6 and E7
override the E5 signal pathway as previous reports have shown that
E6 and E7 oncogenes increase the levels and activity of EGF-receptor
(Akerman et al., 2001; Johnston et al., 1999). It could also be possible
that the differential activity of E5 from HPV-16 and HPV-31 over the
EGF-receptor could be due to a difference in expression levels or
different functional properties attributed to sequence variations.
When we investigated the mechanisms through which E5
promotes cell cycle progression, we found that HPV-16 E5 has the
ability to enhance the down-regulation of p27Kip1 protein levels. Also,
we propose that E5 activity depends on the presence of an active EGF-receptor, as the system could be blocked by the EGF-receptor
inhibitor, tyrphostin-AG1478. Finally, we identiﬁed that Grb2 protein
remains phosphorylated for a longer period of time in E5-expressing
cells, which could suggest that an active signal transduction through
the Ras protein is going on, although this is only a speculation as more
experiments need to be done to deﬁne this part. All together, these
results suggest that HPV-16 E5 regulates entry to the cell cycle,
through the down-regulation of p27Kip1 protein in an EGF dependent
manner and this could be the reason for the larger S-phase cell
population observed in our experiments; probably, this could be an
initiator stage of the transformation process, as has been shown to
happen with the Ras oncoprotein (Gryfe et al., 1997; Takami et al.,
1995). Alternatively, it has been shown that p27Kip1 regulates
cytoplasmic Grb2 in response to EGF-stimulation in a negative
feedback system (Moeller et al., 2003). It has also been shown that
regulation of Grb2/Ras activities has the potential to inﬂuence cell fate
decisions (Schwartz, 1997) and this could be fundamental for E5.
Probably, this oncoprotein plays a key role in the viral life cycle,
maintaining partially differentiated cells into the cell cycle, in order to
generate viral particles.
Because p27Kip1 controls cell division, the deregulation of p27Kip1
has been implicated not only in oncogenesis, but also in tumor
aggressiveness and poor patient survival in many human cancers
(Bloom and Pagano, 2003; Catzavelos et al., 1997; Mori et al., 1997). It
is possible that p27Kip1 protein, an important CDK activity regulator,
could affect cell cycle entry and exit in cancerous cells. It was also
shown that p27Kip1 protein is expressed at high levels in differenti-
ated, non-cycling cells and is low or absent in proliferating cells
(Durand et al., 1998). More recently, it was demonstrated that low
levels of p27Kip1 in transgenic mice (haploinsufﬁcient for p27+/−)
were more susceptible to transformation by the ErbB2/Neu receptor
(member of the ErbB family, which includes the EGF-receptor). These
researchers also showed that loss of both p27Kip1 alleles result in a
decreased susceptibility to ErB2-mediated transformation (Muraoka
et al., 2002). Thus, it seems that titration levels of p27Kip1 into the cell
may determine the function of this protein into the cell cycle. In this
context, we can speculate that HPV-16 E5 maintains low levels of
p27Kip1 in the cell, as this protein is required for cyclin D/Cdk4 activity
(Cheng, et al., 1998, 1999). This Cdk4 activity allows progression
through early G1 and entry to the S phase, ﬁnal effect that was
observed in E5-expressing cells (Fig. 2). At this point, it is not clear,
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deregulates p27Kip1 protein levels impairing the role of this protein as
a cell cycle inhibitor and allowing the cells to switch into a
proliferation stage to permit production of viral proteins. However,
if p27Kip1 low levels persist for long time, because E5 regulation, this
may drive the cells to a transformation process, as it was observed for
the haploinsufﬁcient p27+/− transgenic mice.
We also looked for alterations in EGF-receptor protein levels and
its activity, since it has been reported that E5 can modulate this
receptor (although this point is controversial). Our results support the
hypothesis that E5 prolongs the activity of the EGF-receptor, but
without increasing the protein receptor levels, as has been reported
elsewhere (Gu and Matlashewski, 1995). However, there is a report
demonstrating an elevated number of EGF-receptors, as well as an
increase in the degree of phosphorylation (Straight et al., 1995).
Impaired down-regulation and recycling of the receptors to the cell
membrane has been observed in E5-expressing cells (Straight et al.,
1993). The discrepancy among reports of EGF-receptor modulation
through E5 could be related to the use of different cell lines that
express different levels of the EGF-receptor family members (i.e.
EGFR, erbB-2, erbB-3, and erbB-4). It has been shown that transpho-
sphorylation of ligand-induced homo or hetero-dimers are generated
to modulate the growth regulatory signal (Carraway and Cantley,
1994; Zhang et al., 1996). It is likely that cells used in this work
speciﬁcally ampliﬁed the EGF-receptor signal pathway, since the cells
over-express this receptor. At the same time, it is also possible that
homo-dimers of EGF-receptor switch on a speciﬁc signal cascade that
culminates in the down-regulation of p27Kip1.
In summary, we have examined the role of HPV-16 E5 in cell cycle
progression and found that E5 enhances the down-regulation of
p27Kip1 protein levels in an EGF-receptor-dependent pathway as the
Grb2 protein remains active for longer time in this system. These data
suggest that p27Kip1 is an indirect downstream E5 target that allows
the cells to stay longer into the cell cycle and permits the initiation of a
transformation phenotype.
Materials and methods
Generation of HPV-16 E5-expressing cells
The 1.2 kb fragment from HPV-16 DNA (nucleotides 3761 to 4986)
containing the complete E5 gene (Seedorf et al., 1985) was cloned into
the BamHI site of pcDNA3 plasmid (Invitrogen). The correct
orientation was conﬁrmed by enzymatic restriction analysis and
sequencing. The constructed E5 plasmidwas named pcDNAE5 capable
of expressing the HPV-16 E5 gene.
All cell lines were grown in Dulbecco's Modiﬁed Eagle's
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). NIH 3T3 mouse ﬁbroblasts were obtained from the American
Type Culture Collection (ATCC). The EGFR cell line was a gift of Dr.
D. Lowy (Lab. Cellular Oncology, NCI, NIH, Bethesda, MD, USA) and
this is a NIH 3T3 cell line that over-expresses the human EGF-
receptor (Velu et al., 1989).
Cells were transfected as described previously (Ogiso et al.,
1990) by the lipofection method (Invitrogen) with 5 μg of
pcDNAE5 plasmid which also codes for G418 resistance. After 15
days of selection in DMEM containing 800 μg/ml G418, a pool of
cells from each transfection was obtained and named 3T3E5 and
EGNE5 (NIH 3T3 and EGFR cells expressing E5, respectively).
Parental NIH 3T3 and EGFR cells transfected with pcDNA plasmid
alone were used as controls and labeled as 3T3neo and EGFRneo
cells, respectively. We chose the NIH 3T3 cells to isolate the EGF
system, given to the fact that EGF-receptor is not the primary
driver of proliferation in this cell line. In this way, speciﬁc signals
delivery from the EGF-receptor could be identiﬁed without the
interference of endogenous receptor.Due to the fact that p27Kip1 protein levels are regulated in part by
cell density, we had to adjust the system to a certain cell
concentration in such a way that this factor did not affect the results.
Cell densities were adjusted for all the experiments to 5×103 cells/
cm2 for 3T3 and 3T3E5, and to 3.5×104 cells/cm2 for EGFRneo and
EGNE5 (approximately 90% conﬂuence). These conditions ensure that
the results were reproducible all the time.
RT-PCR analysis
Five micrograms of total RNA was used for reverse transcription
with oligo(dT) primers and the enzyme Mo-MLV RT (Invitrogen).
Ampliﬁcation of each target cDNA was detected after 30 cycles of PCR
at 94 °C for 45 s, 54 °C for 1 min and 72 °C for 2 min, using 1 U of
ULTMA enzyme in each reaction (PerkinElmer Co.). The ﬂanking
primers that include the E5 region (3851 to 4098 bp) of the HPV-16
were used for the ampliﬁcation step: forward oligo-nucleotide E5-
GST1 (5′-GCCCGGAATTCGGACAAATCTTGATACT-3′); reverse oligonu-
cleotide E5-GST2 (5′-GCGCCGCTCGCGTTCATGTAATTAAAAAGCG-3′).
The oligonucleotides ampliﬁed a fragment of 275 bp long that corres-
ponded to HPV-16 E5 ORF.
Cycloheximide (CHX) treatment
CHX was purchased from Sigma and a stock solution of 5 mg/ml
was prepared in ultrapure water and sterilized by ﬁltration. For all the
experiments with CHX, exponentially growing cells were culture for
72 h in DMEM-10% FBS. Finally, cells were exposed 30 min to CHX
treatment (5 μg/ml) prior to EGF-stimulation (25 ng/ml) (Roche) for
the times indicated in the Results section.
Assay for growth in soft agar
For colony formation in suspension, cells were plated on 60 mm
dishes with a bottom layer of 1% agar as described previously (Chen
and Mounts, 1990). Brieﬂy, 1×104 cells were seeded in quadruplicate
in DMEM-10% FBS and 0.4% Noble agar and poured onto previously
prepared 60 mm agar dishes. After 15 days of culture at 37 °C the
number of colonies was counted. Half of the culture cells were
stimulated every other day with 25 ng/ ml EGF.
Cell proliferation assays
Cells were seeded at 3×104 cells/35mmdish in DMEM-10% FBS in
duplicate and stimulated with 25 ng/ ml EGF, every other day for 15
days. Cells were harvested at different periods of time (1, 2, 5 and 7
days) and the total cell number was calculated by counting cells in a
Neubauer chamber. From these data, cell curves were plotted in a
graph and doubling time and saturation density of the different cell
lines were calculated from three independent experiments. A Mann–
Whitney test was run to compare the difference observed between
parental cell lines and the E5-expressing cells and a p value b0.05 was
considered statistically signiﬁcant.
Western blot analysis
Cells were trypsinized, pelleted and lysed in cold RIPA-PBS buffer
(2.7 mM KCl, 1.5 mM KH2PO4, 150 mM NaCl, 8.1 mM Na2HPO4, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA pH 7.3 and
protease inhibitors from Roche), and supplemented with 10 mM
sodium orthovanadate, and 0.5 mM DTT when looking for protein
phosphorylation. Forty micrograms of total protein were resolved by
SDS-PAGE and transferred to PROTEAN nitrocellulose membranes
(Whatman International Ltd.) as described previously (Towbin et al.,
1979). The ﬁlters were blocked with PBS-T buffer (PBS including
0.05% Tween 20) containing 10% skim milk for 2 h at 4 °C. The ﬁlters
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antibody binding was detected by using horseradish peroxidase-
linked goat anti-mouse or anti-rabbit IgG (DAKO) and visualized by
the enhanced chemiluminescence (ECL) detection system (PerkinEl-
mer Co.). Antibodies against p21Waf1, cyclin A, cyclin D1, p27Kip1, anti-
phosphotyrosine and actin were purchased from Santa Cruz Biotech-
nology and monoclonal anti-EGF-receptor from Zymed.
Bands were analyzed by densitometric analysis by using the
ImageJ program (version 1.33u, NIH-USA). In all cases, the density of
the bands was adjusted to the density of the corresponding actin
bands, and the bands of control cells in basal conditions were arbitrary
taken as 100.
Cell cycle analysis by ﬂow cytometry
Cells were seeded at low cell density as mentioned before in
60 mm dishes in DMEM-10% FBS in duplicate and grown for 32 h at
37 °C in 5% CO2/95% air. Cells were stimulated with 25 ng/ ml EGF for
16 h, after which cells were trypsinized, re-suspended in DMEM-10%
FBS and counted. Equal number of cells from each treatmentwas ﬁxed
in 75% ethanol. Cells were centrifuged and stained with 10 μg/ ml of
propidium iodide (PI) in PBS containing 10 μg/ ml RNAse for 1 h at
room temperature in the dark. Finally cells were analyzed by ﬂow
cytometry (FACSCalibur, Beckton Dickinson & Co.) and results
analyzed by the WinMDI 2.8 software.
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